Friday Satellite Symposia
Lymphoid Leukemias, Combination therapy, Antibody Therapy, CLL, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapy sequence, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Technology and Procedures, Molecular testing
Grand Hall C
(Manchester Grand Hyatt San Diego)
Chair:
Brian T. Hill, MD, The Cleveland Clinic Foundation
Disclosures:
Hill: Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Beigene: Consultancy, Honoraria, Research Funding.
Speakers:
Sameer A. Parikh, MBBS, Mayo Clinic
and
Danielle M. Brander, MD, Duke University
Disclosures:
Parikh: Pharmacyclics: Consultancy; Merck: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; MingSight: Consultancy; AbbVie: Consultancy; Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Kite: Consultancy; Novalgen Limited: Consultancy; BeiGene: Consultancy; Amgen: Consultancy. Brander: Nurix: Other: site PI clinical trial (grant paid to institution); NeWave: Other: site PI clinical trial (grant paid to institution); Juno/Celegene/BMS: Other: site PI clinical trial (grant paid to institution); Genentech: Consultancy, Other: site PI clinical trial (grant paid to institution); DTRM: Other: site PI clinical trial (grant paid to institution); Catapult: Other: site PI clinical trial (grant paid to institution); BeiGene: Consultancy, Other: site PI clinical trial (grant paid to institution); AstraZeneca/Acereta: Other: site PI clinical trial (grant paid to institution); ArQule/Merck: Other: site PI clinical trial (grant paid to institution); AbbVie: Consultancy, Other: site PI clinical trial (grant paid to institution); Pharmacyclics: Consultancy, Other: site PI clinical trial (grant paid to institution); TG therapeutics: Other: site PI clinical trial (grant paid to institution); BMS: Other.
On Demand program will be available here December 30, 2024.
Recent advancements in CLL management include evolving treatment strategies, featuring novel targeted therapies and updated clinical guidelines. The NCCN and CCO are proud to present this interactive opportunity to engage with leading experts to discuss the latest evidence and work through challenging cases. Indeed, this satellite symposium is not just a passive learning experience, but an interactive platform for healthcare professionals to stay fully informed and be equipped to apply the latest treatment advances in CLL. This event delivers an in-depth review of the most recent NCCN Guideline updates and innovative clinical approaches, highlighted through immersive case-based discussions. Attendees will glean critical insights into optimizing treatment strategies, fortified by expert recommendations and comprehensive clinical data. The symposium also provides invaluable resources, including NCCN patient handouts, detailed guideline slides, a review of the 2025 algorithm, and interactive Q&A sessions for direct engagement with the distinguished panel.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.